Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019
- PMID: 36680166
- PMCID: PMC9867357
- DOI: 10.3390/v15010126
Secular Trends of Clinical Characteristics and Survival of Hepatocellular Carcinoma in Taiwan from 2011 to 2019
Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer death in Taiwan, and in the past 30-40 years, Taiwan has been committed to its prevention and treatment. We aimed to investigate the secular trends of characteristics and the survival of HCC in recent decades after making increased efforts. Between 2011 and 2019, a total of 73,817 cases were enrolled from the TCR database. The overall male-to-female ratio was 7/3. The overall, male and female mean ages increased from 63.8 to 66.1 years, 62.0 to 64.3 years and 68.3 to 70.4 years, respectively. After dividing by viral etiologies and gender, the mean age showed increasing trends in all subgroups. The proportions of HBV-HCC, HCV-HCC, HBV+HCV-HCC and Non-HBV+non-HCV-HCC were 48.3%, 25.2%, 5.3% and 21.3% in males, compared with 25.5%, 48.6%, 5.3% and 20.5% in females, respectively. The 5-year survival rates of BCLC stages 0, A, B, C and D were 70%, 58%, 34%, 11% and 4%, respectively. The proportion of BCLC stage 0 increased from 6.2% to 11.3%. Multivariate analysis showed that being female, older age, diagnostic year, BCLC stages, hospital level, body mass index, smoking, alcohol consumption, AFP, Child-Pugh classification and HBV/HCV status were independent predictors for survival. In recent decades, the overall survival of HCC in Taiwan has been improving and might be partly associated with increased BCLC 0 and Child-Pugh A patients, while with the consequent age of patients increasing over time. The proportion of viral-related HCC is decreasing, while nonviral-related HCC is increasing.
Keywords: age; gender; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; non-B and non-C viral hepatitis; survival.
Conflict of interest statement
The authors declare no conflict of interest.
Figures







Similar articles
-
Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease.J Chin Med Assoc. 2021 Jun 1;84(6):606-613. doi: 10.1097/JCMA.0000000000000530. J Chin Med Assoc. 2021. PMID: 33871391
-
Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan.Int J Cancer. 2006 Oct 15;119(8):1946-52. doi: 10.1002/ijc.22045. Int J Cancer. 2006. PMID: 16708389
-
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.Medicine (Baltimore). 2016 Apr;95(15):e3284. doi: 10.1097/MD.0000000000003284. Medicine (Baltimore). 2016. PMID: 27082566 Free PMC article.
-
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.Princess Takamatsu Symp. 1995;25:27-32. Princess Takamatsu Symp. 1995. PMID: 8875606 Review.
-
Natural history of chronic hepatitis B REVEALed.J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x. J Gastroenterol Hepatol. 2011. PMID: 21323729 Review.
Cited by
-
Above-Standard Survival of Hepatocellular Carcinoma as the Final Outcome of Comprehensive Hepatology Care Programs in a Remote HCV-Endemic Area.Viruses. 2023 Mar 19;15(3):786. doi: 10.3390/v15030786. Viruses. 2023. PMID: 36992494 Free PMC article.
-
Surveillance Imaging and GAAD/GALAD Scores for Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis.J Clin Transl Hepatol. 2024 Nov 28;12(11):907-916. doi: 10.14218/JCTH.2024.00172. Epub 2024 Oct 14. J Clin Transl Hepatol. 2024. PMID: 39544249 Free PMC article.
-
Role of reimbursement and Physicians' awareness in the survival of sorafenib-eligible advanced hepatocellular carcinoma patients.Kaohsiung J Med Sci. 2024 Jun;40(6):589-598. doi: 10.1002/kjm2.12838. Epub 2024 May 2. Kaohsiung J Med Sci. 2024. PMID: 38695728 Free PMC article.
-
Huangqi fuling decoction inhibits the invasion and metastasis of gastric cancer via the TNF signaling pathway.Sci Rep. 2025 Jun 4;15(1):19628. doi: 10.1038/s41598-025-00920-8. Sci Rep. 2025. PMID: 40467576 Free PMC article.
-
Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis.Cancer Epidemiol Biomarkers Prev. 2024 Dec 2;33(12):1717-1726. doi: 10.1158/1055-9965.EPI-24-0626. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 39240221 Free PMC article.
References
-
- Tateishi R., Uchino K., Fujiwara N., Takehara T., Okanoue T., Seike M., Yoshiji H., Yatsuhashi H., Shimizu M., Torimura T., et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J. Gastroenterol. 2019;54:367–376. doi: 10.1007/s00535-018-1532-5. - DOI - PMC - PubMed
-
- Taiwan Cancer Registry Center Cancer Stastistics. [(accessed on 6 October 2022)]. Available online: https://twcr.tw/?page_id=1855&lang=en.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous